These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 32091409)
1. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409 [TBL] [Abstract][Full Text] [Related]
2. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955 [TBL] [Abstract][Full Text] [Related]
6. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients. Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816 [TBL] [Abstract][Full Text] [Related]
7. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Riedlova P; Janoutova J; Hermanova B Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084 [TBL] [Abstract][Full Text] [Related]
8. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830 [TBL] [Abstract][Full Text] [Related]
9. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243 [TBL] [Abstract][Full Text] [Related]
10. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965 [TBL] [Abstract][Full Text] [Related]
12. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669 [TBL] [Abstract][Full Text] [Related]
13. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088 [TBL] [Abstract][Full Text] [Related]
15. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317 [TBL] [Abstract][Full Text] [Related]
16. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions. Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X Front Genet; 2021; 12():674094. PubMed ID: 34917121 [No Abstract] [Full Text] [Related]
18. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer. Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043 [TBL] [Abstract][Full Text] [Related]
20. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]